RxDoctor Payments DataLook up a doctor →

William Ondo, MD

Neurology · Houston, TXNPI 1851471437

Payments from drug & device makers

$3,064,283in general payments, 2019–2025

Across 2,177 payments — averaging $1407.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$1.2M
  • Neurocrine Biosciences, Inc.$380K
  • Amneal Pharmaceuticals LLC$292K
  • AbbVie$186K
  • Teva Pharmaceuticals USA, Inc.$173K
  • Acadia Pharmaceuticals Inc$156K
  • plus $659K from 52 others
$11,735in research payments, 2019–2025

Across 7 payments — averaging $1676.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$7K
  • Eli Lilly$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Neurocrine Biosciences, Inc.$1K
  • Biogen$54

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biogen17$1,218,353
Neurocrine Biosciences, Inc.414$380,351
Amneal Pharmaceuticals LLC161$292,094
AbbVie(2 entities)260$185,937
Teva Pharmaceuticals USA, Inc.189$173,063
Acadia Pharmaceuticals Inc277$155,751
MDD US Operations, LLC235$150,243
Sunovion Pharmaceuticals Inc.70$134,191
Acorda Therapeutics, Inc137$105,191
Lundbeck LLC10$90,375
Kyowa Kirin, Inc.72$63,903
Merz Pharmaceuticals, LLC71$28,929
Eli Lilly3$17,596
Adamas Pharmaceuticals, Inc.22$16,804
Jazz Pharmaceuticals Inc.14$14,025
Takeda Pharmaceuticals U.S.A., Inc.2$5,000
Ipsen Pharma SAS2$4,655
Azurity Pharmaceuticals, Inc.12$4,436
Veloxis Pharmaceuticals, Inc.1$3,375
Sage Therapeutics, LLC2$3,150
Insightec,inc4$2,940
UCB SA2$2,240
Supernus Pharmaceuticals, Inc.26$2,055
Orphalan Inc1$1,800
UCB, Inc.6$1,563
Osmotica Pharmaceutical Corp.1$1,125
Boston Scientific20$1,033
Medtronic(2 entities)13$831
Noctrix Health, Inc.2$588
Abbott26$550
Avion Pharmaceuticals14$262
Merz North America, Inc.7$204
Ipsen Biopharmaceuticals, Inc9$202
Arbor Pharmaceuticals, Inc.12$193
CSL Behring8$182
Otsuka America Pharmaceutical, Inc.7$145
GE HealthCare6$141
Amgen5$91
Revance Therapeutics, Inc.3$84
SK Life Science, Inc.3$77
Collegium Pharmaceutical, Inc.3$65
Avanir Pharmaceuticals, Inc.3$54
Corium, LLC2$50
Sanofi3$50
Harmony Biosciences LLC2$43
Lilly USA, LLC3$38
Vertical Pharmaceuticals, LLC2$35
Novartis2$32
Piramal Critical Care2$32
Pfizer1$25
Cala Health, Inc.1$21
Impel Pharmaceuticals Inc.1$19
Genentech, Inc.1$18
Electromed, Inc.1$18
Strongbridge US Inc.1$17
Catalyst Pharmaceuticals, Inc.1$14
Grifols USA, LLC1$14
Idorsia Pharmaceuticals US Inc1$13

How this compares

$3,064,283 in reported general payments places this provider in the 95th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas →

Medicare billing

Part B allowed, 2024
$446,086
Medicare patients
395
Services billed
44,648

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Houston

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →